An experimental lung cancer drug held disease in check for 89% of patients in one group.
Revolution Medicines (RVMD) reported Phase 1/2 trial results for RASONQUE (daraxonrasib) in metastatic non-small cell lung cancer (NSCLC) in the New England Journal of Medicine. In a subgroup of 38 patients, the drug achieved a 42% objective response rate, 89% disease control rate, 8.3-month median progression-free survival, and 16.0-month median overall survival. The company is conducting a Phase 3 trial (RASolve 301) comparing RASONQUE with docetaxel. RASONQUE is already FDA-approved for metas
How this was made
The 30-second read
Why it matters
The data provide the first efficacy signal for RASONQUE in non‑G12C RAS‑mutant lung cancer, potentially expanding the drug's market beyond its FDA‑approved pancreatic indication.
Market read
Positive early‑stage data could lift RVMD stock and influence peer biotech valuations in the oncology space.
What to watch
The drug carries notable toxicities in pancreatic trials; regulatory scrutiny could affect timelines.
Background
Revolution Medicines (RVMD) announced NEJM publication of Phase 1/2 data for its RAS‑selective inhibitor RASONQUE in metastatic NSCLC, supporting its ongoing Phase 3 RASolve 301 trial.
Ticker impact
Revolution Medicines released first-in-human Phase 1/2 data for RASONQUE in RAS‑mutant NSCLC, showing 42% response and 89% disease control in a 38‑patient subgroup.
Potential short‑term upside as investors price in efficacy signal; volatility may rise ahead of Phase 3 data.
Phase 1/2 data are material for a biotech; the response rates are strong for a non‑G12C RAS mutant cohort, likely prompting buying interest.
Market effects
Strengthens the broader RAS‑targeted oncology sector and may lift peer biotech valuations.
US biotech market may see modest gains; limited immediate impact on other regions.
Adds to global interest in RAS inhibitors, potentially influencing European and Asian oncology pipelines.
Counterpoint
Early‑stage data may not translate to Phase 3 success; investors should watch for safety signals and enrollment challenges.
Key entities
- companyRevolution Medicines, Inc.
Biotech developer of RASONQUE, listed on Nasdaq (RVMD).
- drugRASONQUE (daraxonrasib)
Oral RAS(ON) multi‑selective inhibitor, FDA‑approved for pancreatic cancer, investigational for NSCLC.
